Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
Co-occurring post-traumatic stress disorder (PTSD) and major depressive disorder (MDD) is the
most common response to trauma; it is associated with poor clinical outcomes and substantial
human disability. Veterans with both PTSD and MDD (PTSD+MDD) have been shown to be at much
greater suicidal risk than individuals with only one of these disorders. Ketamine given as
repeated infusions has been shown to be effective in rapidly reducing PTSD and MDD symptoms
in treatment resistant PTSD+MDD individuals. However, knowledge about the mechanisms
underlying comorbid PTSD and MDD remain limited. The purpose of this study is to use repeated
ketamine infusions as a probe to validate a model of PTSD+MDD that focuses on neuroanatomy
and executive functioning.
Phase:
Phase 1
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute
Collaborator:
Minneapolis Veterans Affairs Medical Center
Treatments:
Anesthetics Central Nervous System Depressants Excitatory Amino Acid Antagonists Excitatory Amino Acids Ketamine Molecular Mechanisms of Pharmacological Action Peripheral Nervous System Agents Pharmaceutical Solutions